SLS SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. (SLS) is expected to report earnings on November 10, 2026, after the market close.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States.
Sector
Healthcare
Industry
Biotechnology